Rani Therapeutics Holdings Inc. Class A Common Stock (RANI)
Stock · NASDAQ · Health Care
$0.6421as of 10/16/2026
Price chart
Active signals
RANI Signal Track Record
How signals performed across all stocks →What RANI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -4.9% | 34% | September 1, 2026 |
| Bollinger Band BreakdownActive now | 21 | -12.8% | 38% | September 16, 2026 |
| Bollinger Band Breakout | 14 | -8.2% | 29% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -2.5% | 40% | March 24, 2026 |
| Any 20-session window (baseline) | -7.4% | 34% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including olig…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 69
- Website
- www.ranitherapeutics.com/
Fundamentals
- 1-day range
- $0.635$0.6977
- Market cap
- $96.76M
- P/E (trailing)
- —
- P/E (forward)
- -3.37
- EPS (trailing)
- $-0.26
- Dividend yield
- —
- Beta
- 0.70
- Avg. volume
- 729.9K
How Rani Therapeutics Holdings Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Rani Therapeutics Holdings Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- RANIRani Therapeutics Holdings Inc. Class A Common Stock$0.641▼ 5.74%Market cap $96.76MP/E —$0.462$3.87
- ALDXAldeyra Therapeutics Inc. Common Stock$0.7▼ 5.02%Market cap $95.91MP/E —$0.8619$5.93
- ONCYOncolytics Biotech Inc. Common Stock$0.5▼ 9.09%Market cap $95.55MP/E —$1.48$4.49
- ZYBTZhengye Biotechnology Holding Limited Class A Ordinary Shares$1.4▼ 6.67%Market cap $99.05MP/E —$0.6155$8.01
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings Inc. Class A Common Stock | $96.76M | — | $0.641 | ▼ 5.74% | $0.462$3.87 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $0.7 | ▼ 5.02% | $0.8619$5.93 |
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.5 | ▼ 9.09% | $1.48$4.49 |
| ZYBT Zhengye Biotechnology Holding Limited Class A Ordinary Shares | $99.05M | — | $1.4 | ▼ 6.67% | $0.6155$8.01 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rani Therapeutics Joins FDA Emerging Technology Platformbenzinga · 10/5/2026
- Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)Yahoo · 10/5/2026
- Rani Therapeutics Joins FDA Emerging Technology PlatformBenzinga · 10/5/2026
Insider Activity
Insider Actions →- Alireza Javadi · September 27, 2026 · Tax Withholding309 @ $0.7592
- Talat Imran · September 27, 2026 · Tax Withholding7.9K @ $0.7592
- Gilson Michelle · August 3, 2026 · Grant247.2K
- Mir A. Imran · July 21, 2026 · Buy36.0K @ $0.69
- Maestas Nicholas · July 17, 2026 · Grant2.00M
- Talat Imran · July 17, 2026 · Buy35.0K @ $0.7198
- Alireza Javadi · June 27, 2026 · Tax Withholding309 @ $0.74
- Talat Imran · June 27, 2026 · Tax Withholding7.9K @ $0.74
- Kate McKinley · June 3, 2026 · Grant805.5K
- Talat Imran · June 3, 2026 · Grant3.80M
- Alireza Javadi · June 3, 2026 · Grant805.5K
- Bailey Vasudev Jaiprakash · May 28, 2026 · Grant123.6K
- Rometty Lisa Ann · May 28, 2026 · Grant123.6K
- Bassan Abraham · May 28, 2026 · Grant123.6K
- Ausiello Dennis A · May 28, 2026 · Grant123.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 43.92M
- Total value held
- $32.08M
- Institutional holders
- 72
- Unknown8.50M
- Unknown8.50M
- Unknown6.50M
- Unknown4.62M
- Unknown3.67M
- Unknown2.33M
- Unknown2.00M
- Unknown1.44M
- Unknown903.3K
- Unknown556.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RANI joins FDA Emerging Technology Platform
Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.
RANI joins FDA Emerging Technology Platform. Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.